Diltiazem in Dilated Cardiomyopathy - DIDI


Diltiazem for mortality in idiopathic dilated cardiomyopathy.


To evaluate the effect of diltiazem on idiopathic dilated cardiomyopathy.

Study Design

Study Design:

Patients Screened: Not given
Patients Enrolled: 186
Mean Follow Up: 24 months

Patient Populations:

Age between 18 and 70 years
LVEF < 50%

Primary Endpoints:

Mortality or listing for transplant

Drug/Procedures Used:

Diltiazem, 30 mg po tid titrated to 90mg po tid (60mg po tid for patients weighing ≤ 50kg)

Principal Findings:

A total of 92 patients were randomized to diltiazem and 94 patients to placebo.

One hundred fifty three patients finished the protocol. 27 patients died or were listed for transplant, and 33 patients withdrew from the study. There were no differences in the primary endpoint between the two groups.

At 24 months, there were statistically significant increases in hemodynamic parameters (cardiac index, stroke work index, systolic and diastolic blood pressure) as well as decreased pulmonary capillary wedge pressure.

Patients who were randomized to diltiazem had better exercise tolerance and subjective well-being.


Although diltiazem appeared to improve hemodynamic and subjective parameters, there was no difference in clinical outcomes observed in this patient population.


1. Circulation 1996; 94:346-52

Clinical Topics: Heart Failure and Cardiomyopathies, Acute Heart Failure

Keywords: Exercise Tolerance, Diltiazem, Stroke, Pulmonary Wedge Pressure, Heart Failure, Systole, Calcium Channel Blockers, Hemodynamics, Cardiomyopathy, Dilated

< Back to Listings